Skip to main
AORT
AORT logo

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc has demonstrated a significant improvement in its operating margin, which reached 17.8%, reflecting a year-over-year increase of 770 basis points and exceeding initial estimates. The company's adjusted EBITDA margin also rose to 18.1%, with a 170 basis point improvement, showcasing robust operational efficiency. Furthermore, management anticipates continued growth in gross margins and EBITDA margins, alongside revenue contributions from new product launches, indicating a strong outlook supported by strategic international expansion and a solid product pipeline.

Bears say

Artivion Inc. faces several significant risks that contribute to a negative outlook, including potential delays in clinical trials, disappointing sales from new products, and the adverse financial impact of GLP-1 weight loss drugs. Recent financial performance has been undermined by a cybersecurity incident, which resulted in a revenue miss of approximately $4.5 million, highlighting vulnerabilities in the company's operational stability and growth trajectory. Additionally, revenue growth has decelerated sharply, from 9.5% in the third quarter to just 3.5% in the fourth quarter of 2024, raising concerns about the sustainability of performance and the effectiveness of new product introductions and international expansion strategies.

Artivion (AORT) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Buy based on their latest research and market trends.

According to 8 analysts, Artivion (AORT) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.